|
|
|
|
Matching up treatments for chronic schizophrenia is a challenge
The pharmacologic options available for the treatment of schizophrenia have never been greater. Yet, clinicians face difficult choices when selecting antipsychotics as they weigh the drugs' risks and benefits. This dilemma was underscored recently when a federally funded study found that of five agents, the most efficacious one, olanzapine (Zyprexa, Lilly), also caused the most weight gain and metabolic changes that could lead to diabetes or heart disease.
|
| |
More>>
|
|
|
|
|
|
New meds and research may improve ADHD treatment
The millions of children coping with attention deficit/hyperactivity disorder (ADHD) have many more treatment options now than they did even 10 years ago. New drugs and newer, longer-lasting formulations of older drugs have given prescribers and patients more to choose from. Improved choice may also mean improved compliance.
|
| |
More>>
|
|
|
|
|
|
The clinical realities of using drugs to fight alcoholism
Advances in the neuroscience of addiction have resulted in novel drug monotherapy and combination therapy treatments for alcoholism. Your understanding of how these drugs work and when to prescribe them is crucial to using them effectively.
|
| |
More>>
|
|
|
|
|
|
Current and future strategies for premature ejaculation
The most common dysfunctions of the ejaculatory process are ejaculation prior to the time desired by the patient and/or his partner (premature or rapid ejaculation), painful ejaculation (dysorgasmia), absence of ejaculation (anejaculation), blood with ejaculation (hematospermia), and retrograde ejaculation (usually postsurgical or associated with α-blocker treatment for benign prostatic hypertrophy). Of these, premature ejaculation (pEJ) is by far the most prevalent, affecting as many as 39% of men in the general community.
|
| |
More>>
|
|
|